Maynard Um
-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on Zenas Biopharma (ZBIO)
-
-
-
-
-
-
-
Zenas Biopharma (ZBIO) PT Raised to $55 at Guggenheim
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Zenas Biopharma (ZBIO)
-
-
-
-
-
-
-
Zenas BioPharma (ZBIO) files mixed shelf
-
-
-
-
-
-
-
ZBIO Investors Have the Opportunity to Lead the Zenas BioPharma Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
-
-
-
-
-
-
-
ZBIO DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Ac
-
-
-
-
-
-
-
ZBIO DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ZBIO
-
470,361 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


